DLBCL
Conference Coverage
When to treat DLBCL with radiotherapy?
Choices depend on factors like evidence of disease, radiologists say.
Conference Coverage
Safely skip PET2 after brentuximab in Hodgkin lymphoma?
Recent data presented at SOHO 2023 suggested that adding brentuximab vedotin to chemotherapy for Hodgkin lymphoma improves outcomes, even without...
From the Journals
ESMO helps hematologists assess new cancer drugs
The group’s new study evaluation tool, the ESMO-MCBS:H, is aimed at helping doctors and others determine the benefit of new blood cancer therapies...
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
Conference Coverage
CBSM phone app eases anxiety, depression in cancer patients
Few patients with cancer have access to psycho-oncologic support.
Conference Coverage
Huge underuse of germline testing for cancer patients
Information from germline genetic testing could affect a patient’s cancer care.
Conference Coverage
DEI training gives oncology fellows more confidence
Only 2%-3% of practicing oncologists are Black or Hispanic/Latino, says Yale Cancer Center doctor.
Feature
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
News
FDA approves glofitamab for DLBCL
Glofitamab, a T cell–engaging bispecific antibody, has been approved by the Food and Drug Administration for adults with DLBCL.
Conference Coverage
Cancer drug shortages spur worry, rationing, and tough choices
Limited supplies of crucial medications are disrupting patient care, oncologists say.
Conference Coverage
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology
A pair of new studies show that drugs can reduce cancer risk when cells are elusive.